plaque psoriasis – media

AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) The Biologics License Application is supported by four Phase 3 studies of more than 2,000 patients with moderate to severe plaque psoriasis (1-3) Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing (4)
- Source: prnewswire
- 661
- April 27, 2018
AbbVie FDA New Approvals plaque psoriasis
Lilly’s Taltz cleared to treat psoriatic arthritis

US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis.
- Source: Pharmatimes
- 501
- December 6, 2017
New Approvals plaque psoriasis Taltz
European Commission Approves TREMFYA® (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Janssen-Cilag International NV announced that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Guselkumab is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis.
- Source: Prnewswire
- 469
- November 27, 2017
interleukin Market Views plaque psoriasis TREMFYA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.